According to the " Herb-Active ingredient-Target " network results, we selected 5 active ingredients and four key target genes to docking, and the docking results that these compounds could bind stably to the active pocket of the key protein, which indicates that XCHT may treat CRC by inhibiting PTGS2, NR3C2, CA2, MMP1. Here, NR3C2 is linked to colorectal carcinoma.